H.C. Wainwright upgraded CytomX Therapeutics (CTMX) to Buy from Neutral with a $5 price target The company reported “highly encouraging” clinical data for its masked EpCAM ProBody Topo-1 ADC, CX-2051, in 25 patients with late-line colorectal cancer, the analyst tells investors in a research note. The firm says that at the highest dose, 43% of patients achieved confirmed responses, which could be more indicative of the response rate upon CX-2051 dose expansion. H.C. Wainwright now sees a path forward for CX-2051 in colorectal cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue